Buchang's profit slump offsets steady pipeline and product expansion
Interim profit and cash flow tumble First-half 2026 revenue fell 11.67% to 5.0 billion yuan and net profit dropped 19.93% to 503 million yuan, while operating cash flow plunged 68.96%. Weaker earnings and cash generation weigh on the stock because they show the core business is shrinking.
This is the single biggest force pushing the stock down this period.
New drug approvals and filings broaden the product line Buchang won approval for Atomoxetine Hydrochloride Oral Solution for ADHD, had a new cancer indication for BC008-1A injection accepted for trials, and gained a license change to make an injectable drug. These add future revenue sources and support the stock.
Shows the pipeline progress that partly offsets the weak earnings.
Small deals add products and fund exposure A subsidiary bought the production approval and technology for Angong Niuhuang Wan for 9.4 million yuan, and Buchang put 100 million yuan into a healthcare equity fund. Both are modest but expand its product portfolio and investment reach.
These are the period's other concrete actions affecting the company's growth outlook.
Medical device development contracts signed A wholly owned subsidiary signed contracts to develop two Class III injectable medical devices for facial volume loss and jaw contour, owning all rights. This opens a new business area beyond drugs, though it is early-stage and years from revenue.
It is a new strategic move that could support longer-term growth.